DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Nefazodone in the Treatment of Social Phobia

Information source: Emory University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Social Anxiety Disorder (SAD)

Intervention: Nefazodone (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Emory University

Official(s) and/or principal investigator(s):
Charles B Nemeroff, MD, PhD, Principal Investigator, Affiliation: Emory University Department of Psychiatry and Behavioral Sciences
Clinton D Kilts, PhD, Study Director, Affiliation: Emory University Department of Psychiatry and Behavioral Sciences
Jeffrey Newport, MD, Study Director, Affiliation: Emory University Department of Psychiatry and Behavioral Sciences

Summary

The purpose of this study is to determine the effectiveness of nefazadone in patients with social anxiety disorder (SAD).

Clinical Details

Official title: Nefazodone in the Treatment of Social Phobia: Functional Brain Imaging and Neuroendocrine Correlates

Study design: Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Detailed description: The purpose of this study is to examine the efficacy of the 5HT2 receptor antagonist nefazadone in SAD, and to explore regional cerebral blood flow in patients with SAD when confronted with a personal phobic stimulus, using positron emission tomography (PET). Changes in cerebral blood flow were correlated with self-rated anxiety measures.

Eligibility

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- DSM-IV diagnosis of generalized social anxiety disorder, males and females between

the ages of 18-65 Exclusion Criteria:

- A history of bipolar disorder, psychotic illness, or any other anxiety disorders,

organic brain disease or active drug or alcohol abuse within one year as assessed by the SCID-P and interview, or a concurrent medical condition that would not be compatible with the study in the opinion of the principal investigator. Patients required to be free of psychotropic or beta-blocker medication for 2 weeks prior to study. Pts taking fluoxetine required to be drug-free for 6 weeks.

Locations and Contacts

Emory University Depatment of Psychiatry and Behavioral Sciences, Atlanta, Georgia 30322, United States
Additional Information


Last updated: November 8, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017